Mental Disorders

Alzheimer’s Blood Biomarkers in Midlife

A US community-based study found that middle-aged adults with blood biomarkers indicating Alzheimer’s disease neuropathology already showed worse cognition and faster cognitive decline years before dementia diagnosis. Researchers analyzed 1,350 participants from the Coronary Artery Risk Development in Young Adults (CARDIA) study who underwent plasma biomarker testing at year 35 (2020–2022). The average participant age was 61 years, 58% were women, 45% were Black, and all participants were free of probable dementia. Investigators measured plasma amyloid-β42 (Aβ42), amyloid-β40 (Aβ40), phosphorylated tau217 (p-tau217), and biomarker ratios including p-tau217/Aβ42 and Aβ42/40, using PET-validated cutoffs to classify Alzheimer’s neuropathology status as negative, intermediate, or positive. Alzheimer’s pathology positivity was identified in 6% of participants using p-tau217/Aβ42, 15% using Aβ42/40, and 4% using p-tau217 alone. Compared with biomarker-negative individuals, participants with positive biomarker profiles performed significantly worse on tests of processing speed and executive function. In addition, biomarker positivity was linked to markedly greater odds of accelerated 5-year cognitive decline, particularly in verbal memory and processing speed. For example, individuals positive for Aβ42/40 had more than fourfold higher odds of accelerated verbal memory decline, while those positive for p-tau217 had nearly fourfold higher odds of accelerated decline in processing speed. No significant associations were observed for global cognition or verbal fluency. Although findings were not entirely consistent across analyses, some associations appeared stronger among women, Black participants, and APOE ε4 carriers. The study highlights that Alzheimer’s-related brain pathology can already be detectable in midlife through simple blood tests and may identify individuals who could benefit from earlier prevention, lifestyle interventions, and future disease-modifying therapies before clinical dementia develops. Source: https://www.thelancet.com/

hyangiu

Recent Posts

Circadian Depression Subtype Linked to More Severe Symptoms and Poorer Antidepressant Response

A circadian subtype of depression is associated with earlier disease onset, more severe clinical features,…

4 days ago

Frequent and Unintentional Daytime Napping Linked to Higher Dementia Risk

A longitudinal study of 995 U.S. older adults found that frequent and unintentional daytime napping…

5 days ago

A Common CD36 Variant of Dilated Cardiomyopathy in Individuals of African Ancestry

A multicohort genetic association study found that the ancestry-enriched CD36 Y325* variant accounted for a…

5 days ago

Exercise Prescription: A Core Component of CVD Prevention and Treatment

An American College of Cardiology scientific statement emphasizes that exercise should be prescribed as a…

5 days ago

Low-Fat Vegan Diet Improves Metabolic Health in T2D

A 16-week low-fat vegan diet was associated with significant reductions in body weight, visceral fat,…

2 weeks ago

Intensive BP Lowering Reduced Cardiovascular Risk but Increased eGFR Decline

A systematic review and meta-analysis of 27 studies involving 88,830 participants found that intensive blood…

2 weeks ago

This website uses cookies.